AI to help end ‘postcode lottery' for vital prostate cancer drug
AI could bring an end to the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said.
A study has discovered that the technology can identify the patients who will benefit most from a "game changer" drug.
Abiraterone, a hormone therapy that blocks testosterone production to prevent the growth of prostate cancer, is approved for NHS use in England for patients with advanced prostate cancer that has spread.
However, it is not approved for men newly diagnosed with high-risk prostate cancer that has not yet spread, even though it has been available for these patients in Scotland and Wales for the past two years.
The new test, developed by Artera, uses AI to detect features invisible to the human eye on images of tumour samples.
The study, led by The Institute of Cancer Research, London, and University College London (UCL), ran the test on biopsy images from more than 1,000 men who took part in the Stampede trial.
Patients were given a score of either biomarker-positive or biomarker-negative.
Researchers found abiraterone reduced the risk of death among biomarker-positive patients from 17 per cent to 9 per cent.
In biomarker-negative patients, the drug cut death risk from 7 per cent to 4 per cent, with researchers suggesting this indicates these men would benefit from standard therapy.
Nick James, a professor of prostate and bladder cancer research at The Institute of Cancer Research, London, and consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, is chief investigator of Stampede and co-led the new study.
He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.
'Access to this life-extending drug is currently a postcode lottery – with those living in Scotland and Wales able to receive the treatment for free.
'The NHS in England has previously decided that it would be too expensive to offer the drug. Since the patent expired in 2022, abiraterone costs just £77 per pack – compared with the thousands of pounds that new drugs cost.
'Previous research by my team has shown that preventing cancer relapses for these men would save more money than the drug costs to purchase.
'I truly hope that this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision not to fund abiraterone for high-risk prostate cancer that has not spread.'
Prof James also highlighted that while abiraterone can have 'spectacular' results, it does have side effects.
'Abiraterone has already hugely improved the outlook for hundreds of thousands of men with advanced prostate cancer,' he said.
'We know that for many men with cancer that has not yet spread, it can also have spectacular results.
'But it does come with side effects and requires additional monitoring for potential issues with high blood pressure or liver abnormalities.
'It can also slightly increase the risk of diabetes and heart attacks, so knowing who is most likely to benefit is very valuable.'
Experts hope the findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, may lead to a change in the availability of abiraterone in England.
Prof Kristian Helin, chief executive of The Institute of Cancer Research, said the drug has been a 'game changer for treatment of prostate cancer'.
'Alongside our mission to find smarter, kinder treatments, we must ensure we are matching the right drugs to the right patients,' he added.
'This research, using artificial intelligence, provides an innovative route to testing prostate cancer patients to determine their treatment.
'I hope that this can be implemented so that all men with prostate cancer who will benefit from abiraterone can do so.'
Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'Prostate Cancer UK has been calling on the UK Government to approve this life-saving, cost-effective drug for over two years.
'These exciting results suggest a way to make this an even more cost-effective approach.
'We therefore echo the researchers' urgent call for abiraterone to be made available to those men whose lives it can save – men who, thanks to this research, we can now identify more precisely than ever before.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Waste depot staff given free health checks as part of initiative in Colchester
STAFF at a waste and recycling depot in Colchester have received free health checks as part of a workplace wellbeing initiative. The checks were conducted at the Shrub End depot by the NHS on the Open Road SOS Bus using a SiSU machine. This initiative identified staff with possible undiagnosed hypertension and formed part of Colchester Council's week-long focus on the health and wellbeing of its staff. The SiSU machine measured not only blood pressure, but also heart rate, body composition, and body mass index. Enthusiastic depot employees hopped aboard the bus for their checks. Mike Watkins, one of the staff members, expressed his gratitude, saying: "It makes us feel valued. "I'm keen to find out about my blood pressure and learn what to do about it if it's not where it should be." Martyn Peck (Image: Suffolk and North East Essex ICB) Worker Darren Hammett added: "I haven't had my blood pressure checked in a while, so I've come along today to find out what it is." The initiative also received positive feedback from staff, including Kevin Cook, who recommended other large workplaces to adopt similar practices. He said: "It's important to look after your health." Similarly, Martyn Peck expressed his desire for reassurance about his health and praised the initiative for aiding the early detection of health problems. Dr. Hasan Chowhan, senior partner at Creffield Medical Group, outlined the significance of the initiative. He said: "High blood pressure is a silent killer. "Many people don't realise they have the condition until they have a heart attack or stroke. "The good news is that it's possible to get it under control. For some that may mean making a few lifestyle changes; others will need to take medications as well. "These simple steps could save your life. "They could also help save your quality of life as both strokes and heart attacks can leave people with long-term disabilities." The initiative was planned with the indispensable support of the NHS Suffolk and North East Essex Integrated Care Board. Nerinda Evans, director of strategic programmes at the care board, said: "We helped to put on this event because we saw it as a great opportunity to talk to people directly about the dangers of undiagnosed high blood pressure. "Prevention is the key thing here. We are actively trying to support people before they have a heart attack or stroke. "We hope everyone at Colchester Recycling Centre will tell their friends and family about the importance of checking your blood pressure to help spread this important message.' The Open Road SOS Bus, commissioned by Essex County Council, plays a vital role in delivering workplace health checks, acting as a key aspect of its services. Stacey Banner, welfare and volunteer manager for the bus, said: "Early detection is crucial in preventing serious health conditions. "We are dedicated to ensuring that all individuals have access to fundamental healthcare services." This event also provided information about the new urgent care dental service, offering NHS treatment in one to seven days for problems like toothache, infections, and broken fillings. John Spence, councillor responsible for children's services, adult social care, public health and integration at Essex County Council, said: "Healthy workforces are happy and competitive workforces. "By taking the stations directly to local people, we are making health checks accessible and helping residents, especially those in manual jobs, take control of their health." The council's proactive approach extends beyond health checks, offering mental health support and other wellbeing aids for staff. Julie Young, deputy leader of Colchester Council and councillor responsible for housing, said: "We're proud to support initiatives that put our staff's wellbeing first. "The health checks at the household waste and recycling depot are a simple but powerful reminder that prevention saves lives. "This is exactly the kind of proactive approach we want to see more of across our workplaces – making it easier for people to take control of their health and stay well." People wanting workplace health checks, mental health support, or other staff wellbeing support can contact:
Yahoo
2 days ago
- Yahoo
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Yahoo
2 days ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
